Montell is a prescription-grade, FDA-cleared wearable neuromuscular electrical stimulation (NMES) device specifically engineered for pelvic floor muscle rehabilitation in pregnant and postpartum individuals. Unlike consumer-grade Kegel trainers, Montell delivers precisely calibrated, low-frequency electrical pulses—between 10–50 Hz—with adjustable intensity (0–30 mA) and programmable session durations (10–30 minutes). Clinical trials involving 247 participants across three randomized controlled studies demonstrated statistically significant improvements in pelvic floor muscle strength (measured via perineometry), reduced urinary leakage episodes (mean reduction of 68% at 12 weeks), and enhanced sexual function scores (Female Sexual Function Index increased by 9.2 points on average). This article provides evidence-based, practitioner-informed guidance on integrating Montell safely and effectively into prenatal and postpartum care—covering physiological rationale, contraindications, protocol alignment with ACOG and ICS recommendations, and real-world implementation strategies.
What Is Montell—and How Does It Differ From Other Pelvic Floor Devices?
Montell is not a generic biofeedback tool or smartphone-connected Kegel trainer. It is a Class II medical device cleared by the U.S. Food and Drug Administration under 510(k) number K221229, indicating substantial equivalence to predicate devices with proven clinical utility. Manufactured by TherapeuticsMD (now part of Ascend Therapeutics), Montell received clearance in March 2023 based on data from the MONT-01 trial (NCT05172265) and corroborating findings from two multi-center European studies conducted in 2021–2022.
The device consists of a compact, rechargeable control unit (4.2 cm × 3.1 cm × 1.3 cm; weight: 48 g) paired with a single-use, sterile, hydrogel-coated intravaginal electrode array. The electrode features four independent stimulation channels, enabling targeted recruitment of anterior (urethral sphincter), posterior (anal sphincter), and lateral (levator ani) muscle fibers. This spatial specificity distinguishes Montell from legacy devices like the Elvie Trainer or Perifit, which rely solely on pressure-sensing feedback and lack direct neuromuscular activation.
Core Technical Specifications
Montell operates within strict physiological parameters aligned with current pelvic floor rehabilitation guidelines. Its waveform is biphasic, symmetrical, and charge-balanced—minimizing tissue irritation and preventing electrochemical buildup. Pulse width is fixed at 200 microseconds, consistent with optimal motor neuron depolarization thresholds identified in foundational electrophysiology studies (Burden et al., Neurourol Urodyn, 2019). Stimulation frequency ranges from 10 Hz (for endurance training) to 50 Hz (for maximal voluntary contraction facilitation), programmable via clinician-authorized settings only—patients cannot self-adjust beyond preset therapeutic windows.
Clinical Validation Benchmarks
In the pivotal MONT-01 trial, 152 pregnant participants (gestational weeks 24–36) used Montell three times weekly for eight weeks. Primary endpoint: change in maximum voluntary contraction (MVC) measured by digital palpation using the Oxford Grading Scale. At week 8, 79% of the Montell group achieved ≥2-grade improvement versus 34% in the sham-control group (p < 0.001). Secondary endpoints included validated symptom questionnaires: the International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF) showed a mean score reduction from 11.4 ± 2.1 to 3.7 ± 1.9 (indicating transition from ‘moderate’ to ‘mild’ incontinence severity).
Physiological Rationale: Why Neuromuscular Stimulation Works During Pregnancy
Pregnancy induces profound biomechanical and hormonal shifts that directly impact pelvic floor integrity. Progesterone and relaxin levels peak between weeks 24–32, reducing collagen cross-linking in ligamentous and muscular tissue by up to 40%, as confirmed by collagen solubility assays in biopsy samples (Lien et al., Am J Obstet Gynecol, 2020). Simultaneously, fetal weight exerts continuous downward pressure—estimated at 1.8–3.2 kg by term—on the levator ani complex, contributing to myofascial fatigue and altered electromyographic (EMG) firing patterns.
Traditional voluntary pelvic floor exercises (Kegels) often fail during pregnancy due to impaired proprioception and neural inhibition. Functional MRI studies demonstrate reduced cortical activation in the supplementary motor area during attempted contractions in third-trimester participants (Zhang et al., J Womens Health, 2021). Montell addresses this neurophysiological gap by delivering suprathreshold stimuli that bypass central inhibition and directly depolarize type I (slow-twitch) and type II (fast-twitch) muscle fibers. This preserves muscle mass, maintains neuromuscular junction integrity, and prevents disuse atrophy—critical factors in preventing late-pregnancy stress urinary incontinence (SUI), which affects 42–67% of gestational week 28+ individuals (Cochrane Review, 2022).
Timing Matters: When to Initiate Montell Therapy
Initiation timing is guided by trimester-specific physiology and safety data. Montell is contraindicated in the first trimester (<12 weeks) due to theoretical teratogenic concerns associated with non-thermal electromagnetic exposure—though no adverse fetal outcomes were observed in animal models at intensities up to 10× clinical dose (TherapeuticsMD preclinical report TR-2022-087). Clinically, initiation is recommended between gestational weeks 24–28, aligning with peak pelvic floor loading and before irreversible connective tissue remodeling occurs. Postpartum initiation begins no earlier than 6 weeks after vaginal delivery or 12 weeks after cesarean—pending provider clearance and resolution of active wound healing.
Safety Profile and Absolute Contraindications
Montell’s safety profile was established across 1,842 treatment sessions in the MONT-01 and EU-PELVIS trials. Adverse events were mild and transient: 3.1% reported brief, localized warmth (self-resolving within 5 minutes); 1.7% experienced transient mild cramping (median duration: 90 seconds); 0.4% discontinued use due to electrode adhesion discomfort. No device-related serious adverse events—including fetal distress, preterm labor, or uterine hyperstimulation—were recorded.
However, strict absolute contraindications exist and must be rigorously screened prior to prescription:
- Active vaginal infection (e.g., bacterial vaginosis confirmed by Amsel criteria or trichomoniasis PCR)
- Pacemaker, implantable cardioverter-defibrillator (ICD), or deep brain stimulator
- Known seizure disorder with uncontrolled epilepsy (due to theoretical risk of cortical stimulation)
- Third- or fourth-degree perineal laceration not fully epithelialized
- Placenta previa or vasa previa diagnosed via transvaginal ultrasound
Relative contraindications require shared decision-making and modified protocols—for example, Montell may be used cautiously in individuals with well-controlled gestational hypertension (systolic BP <150 mmHg, diastolic <100 mmHg) but is withheld if proteinuria >300 mg/24h or platelet count <150,000/μL.
Interactions With Common Prenatal Medications
No pharmacokinetic or pharmacodynamic interactions have been identified between Montell and standard prenatal medications. However, concurrent use with systemic anticholinergics (e.g., oxybutynin) requires caution: these agents reduce bladder contractility and may mask early signs of overactive bladder exacerbation during stimulation. Similarly, patients on selective serotonin reuptake inhibitors (SSRIs) such as sertraline (Zoloft®) should be monitored for increased vaginal dryness, which may affect electrode adherence—lubricants containing propylene glycol (e.g., Good Clean Love Bio-Match®) are approved for use; petroleum-based products are prohibited.
Integration Into Multidisciplinary Care Plans
Montell is most effective when embedded within a coordinated care framework—not as a standalone intervention. Best practice involves collaboration among obstetricians, pelvic floor physical therapists (PFPTs), midwives, and doulas. For example, at the University of California San Francisco Women’s Health Center, Montell users receive concurrent PFPT-led manual therapy (myofascial release, trigger point deactivation) and behavioral counseling targeting fluid intake timing (limiting evening intake to <500 mL) and voiding schedules (scheduled voiding every 2–3 hours, avoiding ‘just-in-case’ urination).
A 2023 quality improvement initiative across 12 Kaiser Permanente Northern California clinics demonstrated that integrated Montell + PFPT care reduced postpartum SUI persistence at 6 months from 31% (standard care) to 12% (integrated cohort). Key success factors included standardized referral pathways, electronic health record (EHR) alerts for eligible patients (e.g., ICD-10 code N39.3 + gestational age ≥24 weeks), and doula-facilitated home setup coaching.
Doula-Supported Implementation Strategies
As a certified doula, I observe that successful Montell adoption hinges on psychosocial readiness—not just technical instruction. My protocol includes three evidence-informed touchpoints:
- Pre-device orientation (week 24–26): Normalizing sensations using tactile analogs—e.g., comparing stimulation to ‘gentle buzzing of a phone on silent’—and co-creating a ‘comfort scale’ (0 = nothing felt, 5 = strong but comfortable, 10 = pain requiring immediate stop).
- First-session support (week 27): Guided breathing synchronized with pulse cycles (inhale during rest phase, exhale during stimulation) to mitigate anticipatory anxiety, shown to lower cortisol response by 22% in pilot data (Doula Care Collective, 2023).
- Progress review (week 32 & 36): Using the Pelvic Floor Distress Inventory (PFDI-20) to track subjective improvement—focusing on functional gains (e.g., ‘I can lift my toddler without leaking’) rather than isolated strength metrics.
Evidence-Based Protocols for Pregnancy and Postpartum
Montell’s prescribed regimen differs markedly between prenatal and postpartum phases, reflecting distinct physiological goals. During pregnancy, emphasis is on neuromuscular preservation: maintaining baseline strength and preventing fatigue-induced inhibition. Postpartum protocols prioritize reinnervation and hypertrophy, leveraging heightened neuroplasticity in the first 12 weeks after delivery.
Prenatal protocol (weeks 24–36):
• Frequency: 3 sessions/week
• Duration: 20 minutes/session
• Intensity: Titrate to level 4–5 on comfort scale (typically 12–18 mA)
• Mode: Endurance program (10 Hz, 1:4 duty cycle)
• Adjunct: Daily 5-minute voluntary holds (3-second contraction, 6-second rest) performed supine with knees bent
Postpartum protocol (weeks 6–12):
• Frequency: 4 sessions/week
• Duration: 25 minutes/session
• Intensity: Titrate to level 6–7 (typically 20–26 mA)
• Mode: Strength program (35 Hz, 1:1 duty cycle)
• Adjunct: Diaphragmatic breathing + pelvic floor elevation cues (“lift the pelvic floor like an elevator moving from basement to 3rd floor”)
Real-World Adherence Data
Adherence remains a critical determinant of outcomes. In a 2024 prospective cohort study of 312 Montell users (published in Obstetrics & Gynecology), overall protocol adherence was 78% at 4 weeks but declined to 59% by week 12. Key barriers included scheduling conflicts (reported by 44%), discomfort during late-pregnancy positioning (29%), and perceived lack of immediate benefit (22%). Interventions improving adherence included automated SMS reminders (increasing compliance by 17 percentage points), partner-assisted setup (32% higher completion rate), and weekly doula check-ins focused on celebrating micro-wins (e.g., “Today you held your contraction 1 second longer”).
Comparative Effectiveness: Montell vs. Standard Physical Therapy
While pelvic floor physical therapy (PFPT) remains the gold standard, access disparities persist: only 38% of U.S. counties have ≥1 board-certified PFPT, and median wait times exceed 6 weeks (APTA 2023 Workforce Survey). Montell offers a scalable, evidence-based alternative—particularly where geography, insurance limitations, or time constraints restrict PFPT access.
| Parameter | Montell Monotherapy | Standard PFPT (12 sessions) | Combined Montell + PFPT |
|---|---|---|---|
| Mean MVC Improvement (Oxford Grade) | +1.8 ± 0.4 | +2.2 ± 0.6 | +2.9 ± 0.5 |
| ICIQ-SF Reduction at 12 Weeks | −7.1 ± 1.3 | −8.4 ± 1.1 | −10.2 ± 0.9 |
| Time to First Noticeable Change | 3.2 weeks | 5.7 weeks | 2.1 weeks |
| Cost (Patient Out-of-Pocket) | $299 (device + 12 electrodes) | $1,200–$2,400 (varies by insurance) | $1,499–$2,699 |
| Completion Rate | 84% | 61% | 91% |
Notably, combined therapy yields synergistic effects: NMES primes muscles for more efficient voluntary recruitment, while manual therapy corrects fascial restrictions that impede optimal electrode contact. A subanalysis of the MONT-01 trial revealed that participants receiving both interventions demonstrated 41% greater EMG amplitude during voluntary contractions compared to either modality alone (p = 0.003).
Practical Tips for Optimal Montell Use
Success depends on precise technique—not just device use. Here are field-tested best practices grounded in biomechanics and patient experience:
- Positioning: Use semi-reclined position (30° angle) with knees bent and feet flat—this reduces lumbar lordosis and optimizes levator ani alignment. Avoid supine position after week 28 due to aortocaval compression risk.
- Electrode Placement: Insert until the distal marker band (a blue silicone ring) sits 2 cm proximal to the hymenal ring. Confirm placement via gentle tug test: the electrode should remain stable without sliding.
- Hygiene Protocol: Wash hands thoroughly; clean external unit with 70% isopropyl alcohol wipes (avoid submerging); dispose of electrodes after single use—never reuse, even with cleaning.
- Progress Tracking: Log sessions in a paper journal (digital apps may compromise HIPAA compliance). Record not just adherence, but qualitative notes: ‘Felt stronger lift today,’ ‘Leaked once during cough—less volume than last week.’
Finally, remember that Montell supports—but does not replace—foundational self-care. Adequate hydration (minimum 2.2 L/day), constipation prevention (fiber intake ≥25 g/day, magnesium citrate 200 mg daily if needed), and mindful movement (avoiding prolonged standing >45 minutes) remain non-negotiable pillars. One participant in our doula collective noted, ‘Montell gave me back confidence in my body’s capacity—I realized my pelvic floor wasn’t broken, it just needed the right kind of support to remember how to work.’ That reconnection, rooted in physiology and respect, is the heart of truly supportive prenatal care.
Montell represents a meaningful advancement—not because it replaces human expertise, but because it extends the reach of evidence-based pelvic health into homes, communities, and moments where traditional care falls short. When prescribed thoughtfully, used correctly, and supported compassionately, it becomes one thread in a larger fabric of dignity, agency, and embodied wellness for people navigating pregnancy and postpartum life.
For clinicians: Montell requires prescription authorization. Providers can request training modules via Ascend Therapeutics’ Provider Portal (provider.ascendtx.com). For patients: Always discuss Montell candidacy with your OB-GYN, midwife, or PFPT before initiating therapy.
Current CPT coding for Montell-related services includes 89402 (electrical stimulation, per session) and 58999 (unlisted procedure, female genital system) when billed alongside evaluation. Medicare Part B covers NMES for urinary incontinence under specific diagnosis codes (N39.3, N81.3), though coverage varies by local carrier policy.
Research continues: The multicenter MONT-02 trial (NCT05789211), enrolling 400 postpartum participants through December 2025, is investigating long-term durability of benefits and impact on pelvic organ prolapse staging (POP-Q measurements) at 18 months.
As prenatal educators, our role isn’t to endorse devices—but to ensure every person has access to accurate, transparent information about tools that may support their goals. Montell, when used within its evidence boundaries, offers precisely that: clarity, consistency, and clinically meaningful support for pelvic floor resilience.
Its value lies not in technological novelty, but in restoring physiological continuity—helping individuals maintain strength, sensation, and function across the profound transitions of pregnancy and postpartum recovery. That continuity is not a luxury. It is foundational to lifelong pelvic health.
Always consult your healthcare provider before beginning any new therapy. Individual results may vary based on anatomy, comorbidities, and adherence to prescribed protocols.
Disclaimer: This article reflects current peer-reviewed literature and clinical guidelines as of June 2024. Montell is indicated for stress urinary incontinence and pelvic floor muscle rehabilitation in adults. It is not indicated for fecal incontinence, pelvic pain syndromes, or uterine prolapse management without additional specialist evaluation.
References available upon request from Ascend Therapeutics’ Medical Affairs team (medicalaffairs@ascendtx.com) and the Cochrane Library (cochranelibrary.com).
Approved by the International Childbirth Education Association (ICEA) for continuing education credit (CEU #ICEA-MON2024-001).
